The article in Blood is a mark of quality and a milestone for the researchers. There is a considerable medical need for new cancer drugs and the development that is taking place within the framework of Vivolux is very much leading edge, as shown by Harvard Medical School and other leading institutions

The published mechanism of action is extremely interesting in the creation of new cancer drugs. We feel very excited about exploring the therapeutic potential of this new drug candidate in clinical studies. Our hope is that our joint research will lead to improved cancer treatment.